Purpuric dermatosis and lymphocytic vasculopathy following SARS-CoV-2 vaccination: Report of two patients
Dermatol Ther
.
2022 Nov;35(11):e15898.
doi: 10.1111/dth.15898.
Epub 2022 Oct 10.
Authors
Zahra Saffarian
1
2
,
Rana Samii
2
,
Alireza Hadizadeh
3
,
Alireza Ghanadan
4
,
Hassan Vahidnezhad
5
6
Affiliations
1
Imam Khomeini Hospital, Tehran University of Medical Science, Tehran, Iran.
2
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
3
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
4
Department of Pathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
5
Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
6
Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
PMID:
36196579
PMCID:
PMC9874540
DOI:
10.1111/dth.15898
No abstract available
Publication types
Case Reports
Letter
MeSH terms
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Pigmentation Disorders*
Purpura* / diagnosis
Purpura* / etiology
SARS-CoV-2
Vaccination
Vascular Diseases*
Substances
COVID-19 Vaccines